Meta-Analysis: The Efficacy and Safety of Paricalcitol for the Treatment of Secondary Hyperparathyroidism and Proteinuria in Chronic Kidney Disease

Table 1

(a) The characteristics of the nine studies, (b) Efficacy indices.

(a)

Reference	Total number; (Paricalcitol/placebo)	Etiology of CKD
		DM	no DM	Treatment	Dosing regimen	Route of administration	Age
[4]	55 (28/27)	26	29	6-month	1 ug/d and 2 ug/d	Oral	18–85
[5]	24 (16/8)	13	11	1-month	1 ug/d and 2 ug/d	Oral	>18
[6]	118 (57/61)	79	4	24-week	1 ug/d and 2 ug/d or 2 ug TIW and 4 ug TIW	Oral	≥18
[7]	78 (40/38)	—	—	12-week	0.04 ug/kg TIW	Intravenous	22–90
[8] TIW	145 (72/73)	88	57	24-week	2 ug TIW and 4 ug TIW	Oral	≥18
[8] QD	75 (35/40)	41	34	24-week	1 ug/d and 2 ug/d	Oral	≥18
[9]	220 (107/113)	129	91	24-week	1 ug/d and 2 ug/d or 2 ug TIW and 4 ug TIW	Oral	≥18
[10]	29 (15/14)	—	—	12-week	0.04 ug/kg or 0.08 ug/kg TIW	Intravenous	2–20
[11]	88 (61/27)	—	—	12-week	iPTH/60 TIW	Oral	≥18
[12]	281 (186/95)	272	0	24-week	1 ug/d and 2 ug/d	Oral	>20

Reference [8] had different methods of administration and gave us the information, respectively.
TIW: treatment with Paricalcitol or placebo thrice weekly.
QD: treatment with Paricalcitol or placebo once a day.

(b)

Reference	[4]	[5]	[6]	[7]	[8] (TIW)	[8] (QD)	[9]	[10]	[11]	[12]	Total number; (P/p)
Total number of patients (P/p)	55; (28/27)	24; (16/8)	118; (57/61)	78; (40/38)	145; (72/73)	75; (35/40)	220; (107/113)	29; (15/14)	88; (61/27)	281; (186/95)	1113; (617/496)
30% decrease in iPTH levels for two consecutive measures (P/p)	—	—	113; (54/59)	78; (40/38)	138; (68/70)	71; (33/38)	209; (101/108)	29; (15/14)	82; (58/24)	—	720; (369/351)
Mean eGFR change from baseline to the final visit (P/p)	—	—	118; (57/61)	—	117; (57/60)	58; (25/33)	175; (82/93)	—	—	—	468; (221/247)
Incidence of hypercalcemia (P/p)	55; (28/27)	—	—	—	140; (69/71)	74; (35/39)	209; (101/108)	29; (15/14)	87; (61/26)	281; (186/95)	875; (495/380)
Incidence of hyperphosphatemia (P/p)	55; (28/27)	—	—	—	140; (69/71)	74; (35/39)	209; (101/108)	—	—	—	478; (233/245)
Elevation in Ca × P product levels (P/p)	—	—	—	—	140; (69/71)	74; (35/39)	209; (101/108)	—	—	—	423; (205/218)
Reduction in proteinuria	55; (28/27)	22; (15/7)	—	—	—	—	—	—	—	272; (184/88)	349; (227/122)

P: Paricalcitol group; p: placebo group.